European Neuropsychopharmacology
Volume 21, Issue 4 , Pages 333-343 , April 2011

Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia

  • Samantha L. McLean

      Affiliations

    • Bradford School of Pharmacy, The University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK
    • ,
  • Ben Grayson

      Affiliations

    • Bradford School of Pharmacy, The University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK
    • ,
  • Nagi F. Idris

      Affiliations

    • Bradford School of Pharmacy, The University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK
    • ,
  • Anne S. Lesage

      Affiliations

    • Dept. Neurosciences, Johnson and Johnson, Pharmaceutical Research and Early Development, Turnhoutseweg 30, 2340 Beerse, Belgium
    • ,
  • Darrel J. Pemberton

      Affiliations

    • Dept. Neurosciences, Johnson and Johnson, Pharmaceutical Research and Early Development, Turnhoutseweg 30, 2340 Beerse, Belgium
    • ,
  • Claire Mackie

      Affiliations

    • Discovery ADME/Tox, Pharmaceutical Research and Early Development, Turnhoutseweg 30, 2340 Beerse, Belgium
    • ,
  • Jo C. Neill

      Affiliations

    • Bradford School of Pharmacy, The University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1274 234677; fax: +44 1274 234660.

Received 6 January 2010 ,Revised 30 April 2010 ,Accepted 12 June 2010.

References 

  1. Abdul-Monim Z, Reynolds GP, Neill JC. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. Journal of Psychopharmacology. 2003;17:57–66
  2. Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research. 2006;169:263–273
  3. Abdul-Monim Z, Reynolds GP, Neill JC. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alteration in parvalbumin-immunoreactive expression in the rat. Journal of Psychopharmacology. 2007;21:198–205
  4. Abi-Dargham A, Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist. 2003;9:404–416
  5. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, et al. Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. Journal of Neuroscience. 2007;27:10,578–10,587
  6. Bodnar AL, Cortes-Burgos LA, Cook KK, Dinh DM, Groppi VE, Hajόs M, et al. Discovery and structure–activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors. Journal of Medicinal Chemistry. 2005;48:905–908
  7. Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, et al. The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. Journal of Pharmacology and Experimental Therapeutics. 2007;321:716–725
  8. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology. 2000;23:351–364
  9. Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends in Pharmacological Sciences. 2005;26:352–360
  10. Burghaus L, Schultz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Research, Molecular Brain Research. 2000;76:385–388
  11. Chan WK, Wong PT-H, Sheu F-S. Frontal cortical α7 and α4β2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology. 2007;52:1641–1649
  12. Deicken RF, Merrin EL, Floyd TC, Weiner MW. Correlation between left frontal phospholipids and Wisconsin Card Sort Test performance in schizophrenia. Schizophrenia Research. 1995;14:177–181
  13. Dias R, Robbins TW, Roberts AC. Dissociable forms of inhibitory control within prefrontal cortex with an analogue of the Wisconsin Card Sort Test: restriction to novel situations and independence from “on-line” processing. Journal of Neuroscience. 1997;17:9285–9297
  14. Freedman R, Hall M, Adler LE, Leonard S. Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry. 1995;38:22–33
  15. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology. 2004;174:45–53
  16. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin. 2007;33:1100–1119
  17. Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the NOR task in the rat. Behavioural Brain Research. 2007;184:31–38
  18. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry. 2004;56:301–307
  19. Hahn B, Shoaib M, Stolerman IP. Involvement of the prefrontal cortex but not the dorsal hippocampus in the attention-enhancing effects of nicotine in rats. Psychopharmacology. 2003;168:271–279
  20. Hajόs M, Hurst RS, Hoffman WE, Krause M, Wall TM, Higdon NR, et al. The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide Hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetised rats. Journal of Pharmacology and Experimental Therapeutics. 2005;312:1213–1222
  21. Hansen HH, Timmermann DB, Peters D, Walters C, Damaj MI, Mikkelsen JD. Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics. Journal of Neuroscience Research. 2007;85:1810–1818
  22. Harris JG, Kongs S, Allensworth D, Martin L, Tregellas J, Sullivan B, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:1378–1385
  23. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, et al. SSR180711 phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biological Psychiatry. 2008;63:92–97
  24. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, et al. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms of schizophrenia. Biochemical Pharmacology. 2009;78:803–812
  25. Hoffmann WE, Schaeffer E, Hajόs M. Auditory Gating in Rat Entorhinal Cortex, Medial Septum and Hippocampus: Modelling Dysfunctional Information Processing Associated with Schizophrenia. In: Society for Neuroscience Abstract, 1023.10. 2005;
  26. Idris NF, Repeto P, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology. 2005;179:336–348
  27. Idris NF, Neill JC, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, et al. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms. Psychopharmacology. 2009;
  28. Jentsch JD, Taylor JR. Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology. 2001;24:66–74
  29. Jones GH, Marsden CA, Robbins TW. Behavioural rigidity and rule-learning deficits following isolation-rearing in the rat: neurochemical correlates. Behavioural Brain Research. 1991;43:35–50
  30. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neuroscience and Biobehavioural Reviews. 2005;29:1021–1034
  31. Leiser SC, Bowlby MR, Comery TA, Dunlop J. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacology & Therapeutics. 2009;122:302–311
  32. Marder SR, Fenton W. Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia Research. 2004;72:5–9
  33. McAlonan K, Brown VJ. Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behavioural Brain Research. 2003;146:97–103
  34. McLean SL, Shemar GK, Idris NF, Marshall KM, Neill JC. Deficits in attentional set-shifting in rats following sub-chronic phencyclidine (PCP) administration, effect of gender. European Neuropsychopharmacology. 2007;17(Supp 4):S275
  35. McLean SL, Beck JP, Woolley ML, Neill JC. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behavioural Brain Research. 2008;189:152–158
  36. McLean SL, Woolley ML, Neill JC. D1-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. European Neuropsychopharmacology. 2009;19:440–450
  37. McLean SL, Woolley ML, Thomas D, Neill JC. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl.). 2009;206:403–414
  38. McLean SL, Jones GA, Neill JC, Davies C, Woolley ML. The effect of sub-chronic phencyclidine on gamma oscillations in an in-vitro electrophysiology preparation. Behavioural Pharmacology. 2009;20(Special issue 1):S103
  39. McLean SL, Grayson B, Harris M, Protheroe C, Bate S, Woolley ML, et al. Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats. Journal of Psychopharmacology. 2010;24:57–63
  40. Miller EK, Erickson CA, Desimone R. Neural mechanisms of visual working memory in prefrontal cortex of the macaque. Journal of Neuroscience. 1996;16:5154–5167
  41. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.. Pharmacology and Therapeutics. 2010;128:419–432
  42. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, et al. Nootropic α7 nicotinic receptor allosteric modulator derived from GABA A receptor modulators. PNAS. 2007;104:8059–8064
  43. Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, et al. SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology. 2007;32:17–34
  44. Quick MW, Lester RAJ. Desensitisation of neuronal nicotinic receptors. Journal of Neurobiology. 2002;53:457–478
  45. Redrobe JP, Nielsen EO, Christensen JK, Peters D, Timmerman DB, Olsen GM. α7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice. European Journal of Pharmacology. 2009;602:58–65
  46. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. Journal of Experimental Therapeutics. 1994;271:1058–1066
  47. Rodefer JS, Basile JL, Callahan PM, Van Natta K, Yeo H, Lowe DA, et al. Attentional set-shifting in rats and monkeys: effects of cholinergic challenges. Society for Neuroscience Abstract. 2007;746.4
  48. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. Journal of Pharmacology and Experimental Therapeutics. 2009;329:459–468
  49. Schreiber R, Dalmus M, De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology. 2002;159:248–257
  50. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27:479–497
  51. Snigdha S, Neill J, Shahid M, Cruise L, Henry B. Brain-derived neurotrophic factor downregulation in rat brain following sub-chronic phencyclidine administration. European Neuropsychopharmacology. 2007;17(Suppl. 4):S258
  52. Snigdha S, Li Z, Dai J, Shahid M, Neill JC, Meltzer H. Effect of PCP to Attenuate DA Efflux in Rats Performing the Object Recognition Task: An In Vivo Investigation. In: Program No. 791.4/ TT40. 2008 Neuroscience Meeting Planner. Washington: Society for Neuroscience; 2008;Online
  53. Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. Journal of Psychopharmacology. 2007;21:440–452
  54. Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B. Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology. 2004;171:306–321
  55. Sutcliffe JS, Marshall KM, Neill JC. Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behavioural Brain Research. 2007;177:117–125
  56. Tait DS, Brown VJ. Difficulty overcoming learned non-reward during reversal learning in rats with ibotenic acid lesions of orbital prefrontal cortex. Annals of the New York Academy of Sciences. 2007;1121:407–420
  57. Thomsen MS, Christensen DZ, Hansen HH, Redrobe JP, Mikkelsen JD. α7 nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology. 2009;56:1001–1009
  58. Timmerman DB, Gronlien JH, Kohlhass KL, Nielsen EO, Dam E, Jorgensen TD, et al. An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognitive-enhancing properties in vivo. Journal of Pharmacology and Experimental Therapeutics. 2007;323:294–307
  59. Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, et al. Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists. Bioorganic and Medicinal Chemistry. 2006;14:8219–8248
  60. White HK, Levin ED. Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology. 2004;171:465–471
  61. Winters BD, Bussey TJ. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. Journal of Neuroscience. 2005;25:4243–4251
  62. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, et al. Discovery of N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2, 3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure–activity relationship. Journal of Medicinal Chemistry. 2006;49:4425–4436
  63. Xiang JZ, Brown MW. Neuronal responses related to long-term recognition memory processes in prefrontal cortex. Neuron. 2004;42:817–829

PII: S0924-977X(10)00116-1

doi: 10.1016/j.euroneuro.2010.06.003

European Neuropsychopharmacology
Volume 21, Issue 4 , Pages 333-343 , April 2011

Article Tools

* Image Usage & Resolution